From the Editor

INTERPHEX was back in full swing with Keynote sessions highlighting cutting-edge technologies that are setting the stage for the bio/pharma industry’s future.

What can we take away from Pfizer's acquisition of Seagen?

This new pioneering phase of mRNA is loaded with potential, but also obstacles and false dawns.

Coverage of COVID-19 vaccines was surprisingly displaced by this year’s astounding oncology and iconoclastic gene therapy “cures.”

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

Content is king in publishing, but interpretation is imperator.

One can only learn the secrets of "fight club" by attending its meetings.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Promising applications for targeted delivery may be cresting the horizon.

As we reach further afield in the molecular universe, we encounter new types of problems to resolve.

Lions and tigers and monkeypox, oh my!

Fresh insight is instrumental in the discussion of novel analytics.

3D cell cultures could provide key avenues to unlocking critical information.

Borrowing is good, but invention is best.

The process of reshaping inevitably leads to fresh insights.

We have broken rules, invented new ones, and engineered stronger institutions and supply chains that will serve us better going forward.

Change of roster does not change the goal line. We are all patients first.

The mission continues. Let science be the guide.

Congress questions FDA on plans to catch up and move forward with facility inspections as pandemic travel restrictions ease.

Vaccines define the path to putting pandemic restrictions and pain in the rear-view mirror.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

Bio/pharma works hard today to change the calendar to tomorrow.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, biopharma science delivers promising results.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies